Slide 1: Half Year Profit of US$1.62 Billion
For immediate release 14 February 2023 Half Year Profit of US$1.62 Billion1,2 Ig franchise growing strongly CSL Vifor progressing well CSL delivered a net profit after tax of $1.62 billion2 for the first half of financial year 2023, steady at CC3. This included one-off costs associated with the acqu
Slide 2: Operational Performance
“CSL’s largest franchise, the immunoglobulin portfolio, grew strongly, up 19% 3, driven by the significant increase in plasma supply and the increased patient demand for our leading Ig products. “The increased plasma supply also drove our albumin growth by 11%3. “Plasma collections growth was impres
Slide 3: CSL Vifor
CSL Vifor • Acquisition of Vifor Pharma Ltd completed 9 August 2022 • Provides CSL with leadership across an attractive portfolio focused on renal disease and diseases of iron deficiency • ~15% revenue growth5 • Integration well advanced and cost synergies on track Innovation & Development • HEMGENI
Slide 4: Outlook
OUTLOOK (at FY22 exchange rates) Commenting on CSL’s outlook, Mr. Perreault said, “Given the challenges we have faced over the pandemic, I am proud of the way CSL has responded and continued to execute on our patient focused strategy. “The strong growth we have seen in plasma collections and our imm
Slide 5: Group Results
Group Results Half year ended December Dec Dec Dec Change 2021 2022 2022 % US$ Millions Reported Reported at CC2,3 Sales 5,808 6,943 7,325 26% Other Revenue / Income 233 241 250 7% Total Revenue / Income 6,041 7,184 7,575 25% Earnings before Interest, Tax, Depreciation 2,479 2,516 2,690 9% & Amortis
Slide 6: Notes to announcement
1 All figures are expressed in US dollars unless otherwise stated 2 Attributable to CSL shareholders 3 Constant currency (CC) removes the impact of exchange rate movements, facilitating the comparability of operational performance. For further detail refer to CSL’s Financial Statements for the Half
Slide 7: Results Presentation for the Half-year ended 31 December 2022
For immediate release 14 February 2023 Results Presentation for the Half-year ended 31 December 2022 Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY) Please find attached the slides for the presentation on the half year results that will be given by the Chief Executive Officer and the Chief Financi
Slide 8: CSL Limited 2023 Half Year Results
CSL Limited 2023 Half Year Results 14 February 2023 Paul Perreault Joy Linton CEO and Managing Director CFO
Slide 9: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, CSL) and CSL's activities as at the date of this presentation. It is information given in summary form only and does not purport to be comple
Slide 10: CEO Overview
CEO Overview Paul Perreault CEO & Managing Director Paul McKenzie Incoming CEO 3
Slide 11: 1H23 Performance
1H23 Performance Ig franchise growing strongly CSL Vifor progressing well CSL Behring CSL Seqirus • Ig franchise growing • Strong sales growth driven $7.18b +25%1 strongly by differentiated products REVENUE • Record levels of plasma • Licence agreement for late- collections stage self amplifying mRN
Slide 12: CSL Behring Revenue up 11%
Revenue up 11%1 Revenue Change1 Therapy $m % Performance Major Brands • Product supply improving in post COVID environment IG 2,227 19% • Strong growth across all geographies especially EU and emerging markets • Strong growth in US & EU driven by improved supply Albumin 585 11% • Albumin growth in C
Slide 13: Operational Highlights
Operational Highlights Plasma Collections • Strong increase in plasma collected +36% with levels now 10% above pre-pandemic • Mexico border re-opened with collections recovering strongly • 7 new centers in US and 1 in Germany • Continued adoption of technology − CSL Plasma donor app – downloads >2.5
Slide 14: CSL Seqirus Revenue up 9%
Revenue up 9%1 Revenue Change1 $m % Performance Major Brands • 9% revenue growth in seasonal influenza Egg Based 123 (33%) vaccines against a backdrop of reduced rates of immunisation • 110 million doses distributed in NH Cell Culture 599 28% • US seasonal influenza vaccines >$1 billion for the seco
Slide 15: Operational Highlights
Operational Highlights Seasonal influenza products Pandemic influenza • 6 months+ age indication for FLUCELVAX® now • Awarded BARDA task order for the manufacture of approved in the US, Argentina, Canada & Taiwan with H5N8 clinical material and Phase 2 clinical study Australia and New Zealand under
Slide 16: CSL Vifor Nephrology
~15% revenue growth2 Integration and cost ~5 months revenue contribution1 synergies on track Revenue $m Major Brands Highlights • US Heart Failure label variation submitted – response Iron 427 expected in Feb 23 • Agreement with large US kidney care provider for ESA portfolio effective Dec 22 • Kors
Slide 17: R&D Highlights – 1H23
R&D Highlights – 1H23 Immunology Respiratory Transplant • Garadacimab (Anti-FXIIa) HAE • Garadacimab (Anti-FXIIa) IPF Phase II study • CSL964 (AAT) treatment of GvHD – Phase III • Phase III study data announced enrolment complete study last patient in • Global submissions started • CSL787 (Neb Ig) P
Slide 18: Significant Target Launch Dates
Significant Target Launch Dates1 FY23 FY24 - FY27 HEMGENIX ® Garadacimab CSL112 FERINJECT® Etranacogene Anti-FXIIa (HAE) ApoA-1 (AMI) Ferric carboxymaltose dezaparvovec (Haem B) (ID) China BERINERT® SC HIZENTRA® Adjuvanted Cell Culture Sparsentan C1 Esterase Inhibitor SCIg 20% Liquid (DM) Influenza
Slide 19: Financials
Financials Joy Linton CFO 12
Slide 20: NPATA
NPATA3 $1,957m +10% $138m FX $1,777m 1H23 NPATA @ CC1 $1,957m Acquired intangible assets amortisation ($96m) Other acquisition adjustments ($190m) $1,818m Tax on adjustments $37m NPATA Attributable to NCI2 $58m 1H23 NPAT @ CC $1,766m NPAT Attributable to NCI2 ($13m) 1H23 NPAT @ CC1 $1,753m 1H22 1H23
Slide 21: CSL Group Financial Highlights
Ig franchise growing strongly CSL Group Includes ~5 months of Vifor financials Financial Highlights 1H22 1H23 1H23 Change 1 1 US$ Millions Rep Rep at CC % R&D Total Revenue 6,041 7,184 7,575 25% Projects within cardiovascular, haematology and immunology Gross Profit3 3,448 4,052 4,275 24% GP %3 57.1
Slide 22: CSL Group 1H23 by Segment
CSL Group 1H23 by Segment CSL CSL Change CSL CSL Change 1 3 1 US$ Millions Behring Seqirus Total % at CC Vifor Group % at CC Sales 4,414 1,653 6,067 10% 876 6,943 26% Other Revenue 142 85 227 1% 13 241 7% Total Revenue 4,556 1,738 6,294 10% 889 7,184 25% Gross Profit4 2,238 1,198 3,436 5% 615 4,052
Slide 23: CSL Behring Gross Margin
CSL Behring Gross Margin $195.00 59.0% $190.00 57.0% Total $185.00 US Onset of CPL55.0% $180.00 COVID-19 impact 53.0% $175.00 $170.00 51.0% • Higher plasma collection costs Gross in COVID environment $165.00 Approx. 9-12 Margin 49.0% $160.00 month inventory • Inflationary pressures cycle time 47.0%
Slide 24: Foreign Currency Impact
Foreign Currency Impact Volatility in world currency markets 1H23 $138m NPATA headwind - largely driven by strong USD Currency Average Rates Realised losses: 1H22 1H23 % change • USD/CNY • GBP/USD USD/EUR 0.86 0.99 15.1% USD/CHF 0.92 0.97 5.4% Unrealised losses: USD/GBP 0.73 0.85 16.4% • USD/EUR • E
Slide 25: FY23 Outlook
FY23 Outlook Guidance Re-affirmed 2H23 Considerations CSL Behring • Strong plasma collections and Ig growth expected to continue • Gene therapy HEMGENIX® US commercialisation FY231 Result Skewed to 1H CSL Seqirus Revenue • Seasonal business with less than 20% of total annual sales in 2H 28 - 30% gro
Slide 26: CSL Contacts
CSL Contacts Mark Dehring VP Investor Relations +61 3 9389 3407 mark.dehring@csl.com.au Bernard Ronchi Investor Relations +61 3 9389 3470 bernard.ronchi@csl.com.au Stephen McKeon Investor Relations +61 3 9389 6798 stephen.mckeon@csl.com.au
Slide 27: Notes
Notes (#) Constant currency removes the impact of exchange Summary NPAT attributable to members of rate movements to facilitate comparability of parent entity operational performance for the Group. This is done in Reported net profit after tax $1,623.2m three parts: a) by converting the current year
Slide 28: Appendix
a riven by Appendix
Slide 29: Appendix A: CSL Behring Key Products 1H23 Revenue
Appendix A CSL Behring - Key Products 1H23 Revenue By Therapy Group $m Therapy Sales Change1 4%, CSL BEHRING Group $m % 10% Other, Other $218 Privigen IVIG 1,306 22% Specialty $436 31% Hizentra SCIG 801 17% IVIG 11%, $1,424 Peri-Operative Albumin Albumin 585 11% Bleeding, $479 Idelvion Haemophilia 3
Slide 30: Appendix B: CSL Vifor & CSL Seqirus Key Products
1H23 Revenue By Therapy Group Appendix B $m CSL Vifor & CSL Seqirus – Key Products 4%, 1%, Pandemic, Other, 5%, 7%, $76 $9 In-Licence, Egg Based, $86 $123 Therapy Sales Change1 CSL SEQIRUS Group $m % 34%, Fluad Adjuvanted 845 7% Cell Culture, Flucelvax Cell culture 599 28% $599 49%, Afluria Egg-base